Detail akcie Xinhua Pharm online

Business Summary: Shandong Xinhua Pharmaceutical Co Ltd is a China-based company mainly engaged in the development, manufacturing and sales of chemical raw materials, pharmaceutical preparations and chemical products. The Company operates three segments. The Chemical Raw Materials segment is mainly engaged in the development, manufacturing and sales of raw materials for antipyretics and analgesics such as caffeine series, ibuprofen series, aspirin series, dopamine series, barbiturates and pipemidic acid. The Pharmaceutical Preparations segment is mainly engaged in the development, manufacturing and sales of tablets, injections and capsules such as pipemidic acid tablets, aminopyrine and nimodipine tablets. The Pharmaceutical Intermediates and Other Products segment is mainly engaged in the development, manufacturing and sales of pharmaceutical intermediates and other products. The Company mainly operates its business in the domestic market and overseas markets such as the Americas and Europe.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Shandong Xinhua Pharmaceutical Co Ltd revenues decreased 2% to RMB4.64B. Net income decreased 16% to RMB223.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects General & Administrative Expenses increase of 19% to RMB215.1M (expense), Other Operating Income decrease of 41% to RMB20.8M (income).